Nuvalent Inc (NUVL) Appoints Michael L. Meyers to its Board

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. DPZ
2. NVDA
3. DRS
4. GS
5. ACI
6. BAC
7. JPM
8. AVAV
9. UNH
10. ORCL

Go back to Nuvalent Inc (NUVL) Appoints Michael L. Meyers to its Board

Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors

October 6, 2022 6:30 AM EDT

CAMBRIDGE, Mass., Oct. 6, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Michael L. Meyers, M.D., Ph.D., to its Board of Directors. An experienced drug developer and medical oncologist who has contributed to the successful development and commercialization of multiple new therapies for patients with cancer, Dr. Meyers has served as a Senior Clinical Advisor to Nuvalent since 2020.

... More